Zogenix, Inc. is an innovative pharmaceutical company committed to developing and commercializing unique therapies that address specific clinical needs for people living with Central Nervous System (CNS) disorders.
Our focused strategy centers on advancing late-stage product candidates and identifying clear pathways for clinical development and regulatory strategies in order to provide access to differentiated medicines.
We continually review opportunities identified by our business development team and strategic investment partners. To discuss potential business development opportunities, please contact:
We seek partners who share our commitment to significantly improve daily functioning for patients living with certain CNS disorders through the development and commercialization of differentiated products. Our current business development priorities are:
- Identifying differentiated, late-stage product development candidates in the therapeutic area of CNS for acquisition and further development
- Seeking a global development and commercialization partner for Relday, our proprietary subcutaneously injected formulation of once-monthly risperidone for the treatment of schizophrenia
For more information related to our proprietary needle-free subcutaneous injection delivery system, DosePro, please go to www.DOSEPRO.com.